Table 1. Immunodeficiency cohort on Ig-replacement treatment.
| PRIMARY | PROBABLE PRIMARY | SECONDARY | PROBABLE SECONDARY | UNKNOWN | |
| TOTAL | 113 | 13 | 26 | 13 | 2 |
| Median age (range) | 45 (17–91) | 52 (30–81) | 64.5 (40–82) | 58 (28–79) | 75.5 (74–77) |
| Male | 47 | 5 | 10 | 5 | 1 |
| Female | 66 | 8 | 16 | 8 | 1 |
| CVID | 79 (69.9%) | 79 (69.9%) | - | - | - |
| Non-inflammatory CVID | 63 | - | - | - | - |
| Inflammatory CVID | 16 | - | - | - | - |
| Probable CVID | - | 8 | - | - | - |
| HYPOGAMMAGLOBULINAEMIA | 5 (4.4%) | 3 (23.1%) | 21 (80.8%) | 9 (69.2%) | 2 (100%) |
| SPECIFIC OR SUBCLASS DEFICIENCY | 10 (8.9%) | 2 (15.4%) | 4 (15.4%) | 4 (30.8%) | - |
| AGAMMAGLOBULINAEMIA | 12 (10.6%) | - | - | - | - |
| XLA | 11 | - | - | - | - |
| Autosomal agammaglobulinaemia | 1 | - | - | - | - |
| OTHER | 7 (6.2%) | - | 1 (3.8%) | - | - |
| Combined deficiency | 1 | - | 1 | - | - |
| Good syndrome | 1 | - | - | - | - |
| ALPS | 1 | - | - | - | - |
| Ataxia telangiectasia | 1 | - | - | - | - |
| HyperIgE syndrome | 1 | - | - | - | - |
| WHIM syndrome | 2 | - | - | - | - |
CVID indicates common variable immune deficiency; ALPS, autoimmune lymphoproliferative syndrome; and WHIM, warts hypogammaglobulinaemia infections and myelokathexis syndrome.